Successful long-term treatment of philadelphia chromosome-negative myeloproliferative neoplasms with combination of hydroxyurea and anagrelide

Clinical Lymphoma, Myeloma and Leukemia

Volumn 13, Issue SUPPL. 2, 2013, Pages

  Ahn, Inhye E ^a   Natelson, Ethan ^a   Rice, Lawrence ^a  

^a HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

Anagrelide; Essential thrombocythemia; Hydroxyurea; Polycythemia vera; Thrombosis

Indexed keywords

ANAGRELIDE; HYDROXYUREA;

ADULT; ARTERIAL THROMBOEMBOLISM; ARTERY THROMBOSIS; ARTICLE; CLINICAL ARTICLE; FEMALE; FOLLOW UP; HEADACHE; HUMAN; LEUKOCYTE COUNT; LONG TERM CARE; LOW DRUG DOSE; MALE; MEDICAL RECORD REVIEW; MONOTHERAPY; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDER; PHILADELPHIA 1 CHROMOSOME; POLYCYTHEMIA VERA; RECTUM HEMORRHAGE; THROMBOCYTHEMIA; TREATMENT DURATION; TREATMENT RESPONSE; VENOUS THROMBOEMBOLISM;

ANAGRELIDE; ESSENTIAL THROMBOCYTHEMIA; HYDROXYUREA; POLYCYTHEMIA VERA; THROMBOSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; HYDROXYUREA; MALE; MIDDLE AGED; MYELOPROLIFERATIVE DISORDERS; PHILADELPHIA CHROMOSOME; POLYCYTHEMIA VERA; QUINAZOLINES; RETROSPECTIVE STUDIES; THROMBOCYTHEMIA, ESSENTIAL; THROMBOSIS;

EID: 84889044017     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2013.05.015     Document Type: Article

References (22)

1. C.N. Harrison, P.J. Campbell, and G. Buck Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia N Engl J Med 353 2005 33 45
2. S. Cortelazzo, G. Finazzi, and M. Ruggeri Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis N Engl J Med 332 1995 1132 1136
3. R. Latagliata, A. Spadea, and M. Cedrone Symptomatic mucocutaneous toxicity of hydroxyurea in Philadelphia chromosome-negative myeloproliferative neoplasms: the Mister Hyde face of a safe drug Cancer 118 2012 404 409
4. J. Thachil, and V. Martlew Phenotypic implications of a co-existent haemorrhagic and thrombotic genotype Blood Coagul Fibrinolysis 23 2012 232 234
5. M. Steurer, G. Gastl, and W.W. Jedrzejczak Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile Cancer 101 2004 2239 2246
6. T. Barbui, G. Barosi, and G. Birgegard Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet J Clin Oncol 29 2011 761 770
7. R. Tibes, and R.A. Mesa Blood consult: resistant and progressive essential thrombocythemia Blood 118 2011 240 242
8. S. Swerdlow, E. Campo, and N. Harris WHO Classification of Tumours of Haematopoietic and Lympoid Tissues 2008 IARC Press Lyon, France
9. C. Rozman, M. Giralt, and E. Feliu Life expectancy of patients with chronic nonleukemic myeloproliferative disorders Cancer 67 1991 2658 2663
10. A.P. Wolanskyj, S.M. Schwager, and R.F. McClure Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors Mayo Clin Proc 81 2006 159 166
11. A. Carobbio, J. Thiele, and F. Passamonti Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients Blood 117 2011 5857 5859
12. S. Cortelazzo, P. Viero, and G. Finazzi Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia J Clin Oncol 8 1990 556 562
13. F. Cervantes, A. Alvarez-Larrán, and C. Talarn Myelofibrosis with myeloid metaplasia following essential thrombocythaemia: actuarial probability, presenting characteristics and evolution in a series of 195 patients Br J Haematol 118 2002 786 790
14. G. Finazzi, V. Caruso, and R. Marchioli Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study Blood 105 2005 2664 2670
15. M. Bjorkholm, A.R. Derolf, and M. Hultcrantz Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms J Clin Oncol 29 2011 2410 2415
16. C. Harrison, J.J. Kiladjian, and H.K. Al-Ali JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis N Engl J Med 366 2012 787 798
17. S.P. Verstovsek, F. Passamonti, and A. Rambaldi A phase 2 study of INCB018424, an oral, selective JAK1/JAK2 inhibitor, in patients with advanced polycythemia vera (PV) and essential thrombocythemia (ET) refractory to hydroxyurea ASH Annual Meeting Abstracts 114 2009 (abstract 311)
18. A.R. Moliterno, E. Hexner, and G.I. Roboz An open-label study of CEP-701 in patients with JAK2 V617-positive PV and ET: update of 39 enrolled patients ASH Annual Meeting Abstracts 114 2009 (abstract 753)
19. R. Marchioli, G. Finazzi, and R. Landolfi Vascular and neoplastic risk in a large cohort of patients with polycythemia vera J Clin Oncol 23 2005 2224 2232
20. A. Christoforidou, D. Pantelidou, and A. Anastasiadis Hydroxyurea and anagrelide combination therapy in patients with chronic myeloproliferative diseases resistant or intolerant to monotherapy Acta Haematol 120 2008 195 198
21. P.A. Beer, W.N. Erber, and P.J. Campbell How I treat essential thrombocythemia Blood 117 2011 1472 1482
22. P.A. Beer, and A.R. Green Pathogenesis and management of essential thrombocythemia Hematology Am Soc Hematol Educ Program 2009 621 628